NCT06108544 is a Phase 3 clinical trial of TAK-279 in Plaque Psoriasis, sponsored by Takeda.

Who is sponsoring NCT06108544?

NCT06108544 is sponsored by Takeda.

What drugs are being tested in NCT06108544?

Interventions in NCT06108544: TAK-279, Placebo, Apremilast.

What condition does NCT06108544 study?

NCT06108544 studies Plaque Psoriasis.

Is NCT06108544 still recruiting?

NCT06108544 is currently completed. Last updated 20 November 2025.

Last reviewed 2025-11-20 · How we verify

NCT06108544

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Completed Phase 3 Last updated 20 November 2025

What this trial tests

Phase 3 trial testing TAK-279 in Plaque Psoriasis in 1,108 participants. Completed in 7 November 2025.

Timeline

6 November 2023

Primary endpoint
6 December 2024

7 November 2025

Quick facts

Lead sponsor	Takeda
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	1,108
Start date	6 November 2023
Primary completion	6 December 2024
Estimated completion	7 November 2025
Sites	217 locations across France, Greece, United Kingdom, Germany, Hungary, Israel, Poland, Argentina

Drugs / interventions tested

TAK-279 — full drug profile →
Placebo
Apremilast (APREMILAST) — full drug profile →

Conditions studied

Plaque Psoriasis — all drugs for Plaque Psoriasis →

Sponsor

Takeda — full company profile →

Who can join

18 and older, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.
Carmona-Rocha E, Rusiñol L, Puig L. · · 2024 · cited 28× · PMID 38399292 · DOI 10.3390/pharmaceutics16020239
Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial.
Armstrong AW, Gooderham M, Lynde C, Maari C, et al · · 2024 · cited 21× · PMID 39167366 · DOI 10.1001/jamadermatol.2024.2701
Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents.
Drakos A, Torres T, Vender R. · · 2024 · cited 21× · PMID 38258121 · DOI 10.3390/pharmaceutics16010111
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.
Elbuluk N, Armstrong AW, Vender R, Bhutani T, et al · · 2026 · PMID 42143206 · DOI 10.1007/s13555-026-01738-6
Probing Allosteric Kinase Modulators as Next Game-Changers in Fighting Neurodegeneration.
Roggiolani E, Rosini M, Minarini A, Basagni F. · · 2026 · PMID 42041106 · DOI 10.1021/acs.jmedchem.5c03783

Verify or expand the search:

Other trials of TAK-279

Trials testing the same drug.

NCT06550076 — A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis · Phase 3 · active not recruiting
NCT06111547 — A Study of TAK-279 in Healthy Chinese Adults · Phase 1 · completed
NCT06258265 — A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements · Phase 1 · completed
NCT06254950 — A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to · Phase 2 · recruiting
NCT06290050 — A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults · Phase 1 · completed

Other recruiting trials for Plaque Psoriasis

Currently open trials in the same condition.

NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting

Other Takeda trials

Trials by the same sponsor.

NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06108544 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Takeda
Last refreshed: 20 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06108544.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing